---
title: "BriaCell Gains Sixth Position DSMB Recommendation For Phase 3 Breast Cancer Study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287636056.md"
description: "BriaCell Therapeutics Corp. (BCTX) received its sixth positive recommendation from the Data Safety Monitoring Board for its Phase 3 Bria-ABC study in metastatic breast cancer, with no safety concerns noted. The trial, under FDA Fast Track designation, evaluates Bria-IMT with an immune checkpoint inhibitor. CEO Dr. William V. Williams called it a significant milestone. BCTX stock closed at $3.49, down 6.18%, and is trading at $3.34 in pre-market, down 4.30%."
datetime: "2026-05-26T12:40:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287636056.md)
  - [en](https://longbridge.com/en/news/287636056.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287636056.md)
generator: "portal-rs"
---

# BriaCell Gains Sixth Position DSMB Recommendation For Phase 3 Breast Cancer Study

(RTTNews) - BriaCell Therapeutics Corp. (BCTX) a clinical-stage biotechnology company developing novel immunotherapies, announced that the independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation for the company's pivotal Phase 3 Bria-ABC study in metastatic breast cancer.

The DSMB review found no safety concerns and advised that the trial continue without modifications. The study, evaluating Bria-IMT in combination with an immune checkpoint inhibitor, is being conducted under FDA Fast Track designation, underscoring the significant unmet medical need in metastatic breast cancer.

CEO and President Dr. William V. Williams described the milestone as "another step forward" in advancing BriaCell's immunotherapy approach for patients with urgent unmet needs.

BriaCell's program highlights the favorable safety and tolerability profile of its therapy, with DSMB meetings held quarterly to ensure ongoing oversight.

BCTX has traded between $2.98 and $36.90 over the past year. The stock closed Friday's trading (May 22, 2026) at $3.49, down 6.18%. In pre-market trading Tuesday the stock is trading at $3.34, down 4.30%. 

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [BCTX.US](https://longbridge.com/en/quote/BCTX.US.md)
- [BCTXW.US](https://longbridge.com/en/quote/BCTXW.US.md)
- [BCTXZ.US](https://longbridge.com/en/quote/BCTXZ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)
- [BCTXL.US](https://longbridge.com/en/quote/BCTXL.US.md)

## Related News & Research

- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [BriaCell subsidiary BriaPro reports $1.32M assets, $299,950 cash after sCD80 license acquisition](https://longbridge.com/en/news/291003611.md)
- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**